《新股消息》奈雪的茶(02150.HK)首日孖展超購142倍 和黃醫藥(00013.HK)未足額
內地茶飲品牌奈雪的茶(02150.HK)首日招股,綜合券商數據,截至下午約6時,合共借出孖展認購額近728.6億元,當中耀才借出近169億元,輝立借出133億元,以公開發售部分集資5.09億元計,超額認購逾142倍。
另外,同爲首日招股的和黃醫藥(00013.HK)(HCM.US),暫錄得孖展額近2.77億元,以公開集資5.85億元計認購率僅47.3%。
奈雪的茶及和黃醫藥的招股期料於下週三(23日)結束,同於30日上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.